Nurse Practitioner Nursing
Resume:
CURRICULUM VITAE
Amy Lynne Goodrich RN, B.S.N., M.S.N., C.R.N.P.-A.C.
Current Appointments:
****- ******* ******** *********- *******, Johns Hopkins School of Medicine
2005- Present Manager, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Medical Oncology Research Nurses
2001- Present Manager, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Hematologic Malignancies Research Nurses
2001-Present Nurse Practitioner, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Hematologic Malignancies
Addresses
Office: 201 North Broadway, Room 9172
Baltimore, MD 21287
Office: 410-***-****
Fax: 410-***-****
E-mail: *******@****.***
Home: 1929 Calvary Road
Bel Air, MD 21015
Education and Training:
1985-1989 BSN, University of Pittsburgh, Pittsburgh, PA
1998-2000 MSN, Acute Care Nurse Practitioner, Johns Hopkins University, Baltimore, MD
Professional Experience :
1989 - 1993 Clinical Nurse, Adult Solid Tumor and Bone Marrow Transplant Unit, The Johns Hopkins Oncology Center
1993 - 1996 Senior Clinical Nurse, Adult Solid Tumor and Bone Marrow Transplant Unit, The Johns Hopkins Oncology Center
1996 - 1997 Nurse Clinician III, Adult Solid Tumor and Bone Marrow Transplant Unit and In-patient / Out-patient Bone Marrow Transplant Clinic, The Johns Hopkins Oncology Center
1998- 2001 Research Nurse, The Johns Hopkins Oncology Center, Division of Hematologic Malignancies
2001- Present Acute Care Nurse Practitioner, The Johns Hopkins Kimmel Cancer Center, Division of Hematologic Malignancies
2001-2005 Manager of The Johns Hopkins Kimmel Cancer Center, Division of Hematologic Malignancies Research Nurses
2005- Present Manager, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology Research Nurses
RESEARCH ACTIVITIES
Publications and Abstracts:
1.Hanson, J, Ohley, K, Goodrich, A. A comparison of autologous bone marrow transplantation for breast cancer versus acute leukemia: nursing practice issues. Oncology Nursing Society Congress, Orlando, FL, May, 1993.
2.Flinn, IW, O’Donnell, P, Noga, SJ, Vogelsang G, Grever, MR, Goodrich, A, Abrams, R, Marcellus, D, Miller, CB, Jones, RJ, and Ambinder, RF. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL. Blood 92(10) suppl 1 (pt 1):2673a, 1998.
3.Flinn IW, O’Donnell P, Noga SJ, Moss T, Loper K, Grillo-Lopez A, Kunkel L, Vogelsang G, Goodrich A, Abrams R, Lopategui JR, Jones RJ, and Ambinder RF. In vivo purging with Rituximab during stem cell transplantation for indolent lymphoma. 41st Annual Meeting of the American Society of Hematology, December 3-7, New Orleans, 1999.
4.Byrd JC, Grever MR, Davis B, Lucas MS, Park K, Goodrich A, Morrison C, Murphy T, Kunkel L, Grillo-Lopez A, Waselenko JK, Flinn IW. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL) small lymphocytic lymphoma (SLL): a feasible and active regimen. 41st Annual Meeting of the American Society of Hematology, December 3-7, New Orleans, 1999.
5.Flinn IW, O’Donnell P, Noga SJ, Borowitz M, Vogelsang G, Grever MR, Goodrich A, Abrams R, Marcellus D, Miller CB, Jones RJ, Ambinder RF. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL. Annals of Oncology (10) suppl 3: 75, 1999.
6.Flinn IW, O’Donnell P, Noga SJ, Vogelsang G, Grever MR, Goodrich A, Abrams R, Marcellus D, Miller CB, Borowitz M, Jones RJ, Ambinder RF. Rituximab in vivo purging and adjuvant immunotherapy during PBSC transplant for NHL. International Bone Marrow Transplant Registry & Autologous Blood & Marrow Transplant Registry February 28 – March 3, 1999.
7. Bryd JC, Grever MR, Willis CR, Waselenko JK, Park K, Goodrich A, Lucas MA, Shinn C, Diehl LF, Flinn IW. Theophylline, pentostatin, and chromabucil: A dose escalation study to modulate intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Cancer Investigation (18) suppl 1: 114, 2000.
8. Flinn IW, O’Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S, Marcellus D, Borowitz M, Jones R, Ambinder RF. Immunotherapy with Rituximab During Peripheral Blood Stem Cell Transplant for Non-Hodgkin’s Lymphoma. Biology of Blood and Marrow Transplantation 2000, 6: 628-632.
9. Byrd JC, Grever MR, Willis CR, Waselenko JK, Park K, Goodrich A, Lucas MA, Shinn C, Diehl LF, Flinn IW. Theophylline, pentostatin, and chromabucil: A dose escalation study to modulate intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Cancer Invest (18) suppl 1: 114, 2000.
10. Bannerji R, Pearson M, Flinn IW, Shinn CA, Goodrich A, Lucas M, Byrd J. Cell sruface complement inhibitors and CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy. 42nd Annual Meeting of the American Society of Hematology, December 1-5, San Francisco, 2000.
11. Byrd JC, Waselenko JA, Shinn CA, Willis CR, Park K, Goodrich A, Lucas M,
Gerver MR, Flinn IW. Biologic study of theophylline followed by pentostatin
and chlorambucil: favorable activity concurrent with in vivo down-modulation of bcl-2 in chronic lymphocytic leukemia cells. 42nd Annual Meeting of the American Society of Hematology, December 1-5, San Francisco, 2000.
12. Byrd JC, Murphy T, Lucas MS, Howard R, Goodrich A, Park K, Pearson M, Buj
V, Waselenko JK, Grever MR, Flinn IW. Thrice weekly rituximab demonstrates
significant activity in chronic lymphocytic leukemia. 42nd Annual Meeting of the
American Society of Hematology, December 1-5, San Francisco, 2000.
13.Goodrich A, Flinn IW, Morrison C. A prospective study to evaluate the nursing management of initial rituximab infusions in outpatient settings. 42nd Annual Meeting of the American Society of Hematology, December 1-4, San Francisco, Blood 96(11) suppl 1 (pt 2):237b, 2000
14.Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Buj V, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. Rituximab using a thrice weekly dosing schedule in B-cell CLL and SLL demonstrates clinical activity. J Clin Oncol 2001, 19(8): 2153-64.
15.Douglas TT, Goodrich A, Brown K, Finely J. Incorporation of clinical trials content into nursing orientation and continuing education. 29th Annual Congress of the Oncology Nursing Society, May, San Diego, 2004
16.Waselenko JK, Reese A, Park K, Lucas M, Goodrich A, Willis CR, Diehl LF, Grever M, Byrd JC, Grever MR, Flinn IW. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Ann Hematol 2006, 85: 301-307.
17.Goodrich A, Emerging therapeutic options for B-cell disorders: Idiopathic thrombocytopenic purprua and chronic lymphocytic leukemia. Clinical Journal of Oncology Nursing 2007, 11(1): 23-36.
18.Goodrich A, Dauses T, Krumm S. One institution’s approach for obtaining insurance clearance for oncology patients enrolling in clinical trials. Accepted for podium presentation at 32nd Annual Congress of the Oncology Nursing Society, Las Vegas, 2007
19.Murphy K, Cohen J, Goodrich A, Long P, Griffin C. Constitutional duplication of a region of chromosome Yp encoding AMELY, PRKY, and TBL1Y: implications for sex chromosome analysis and bone marrow engraftment analysis. Journal of Molecular Diagnostics 2007, 9(3): 408-413.
20.Blumel S, Goodrich A, Martin C, Dang N. Bendamustine: A novel cytotoxic agent for hematologic malignancies. Clinical Journal of Oncology Nursing 2008, 12(5): 799-806.
21.Goodrich, A. Bendamustine. Journal of the Advanced Practitioner in Oncology 2010, 1(1): 51-54.
22.Goodrich, A. A case study approach to chronic myelogenous leukemia. Journal of the Advanced Practitioner in Oncology 2010, 1(3): 171-181.
23.Goodrich, A. Update on the management of follicular lymphomas. Journal of the Advanced Practitioner in Oncology 2011;2 (Suppl 2):27–34
24.Goodrich, A. (2013) Mature B-Cell Malignancies in ONS Hematologic Malignancies in Adults. Pp. 201-362. Pittsburgh, Pennsylvania. Oncology Nursing Society.
25.Goodrich, A. (2017) Lymphomas: Non-Hodgkin Lymphoma and Hodgkin Lymphoma in Mosby’s Oncology Nursing Advisor: A Comprehensive Guide to Clinical Practice, 2nd Edition. Pp 122-135. St. Louis, Missouri. Elsevier.
26.Goodrich, A., Wagner-Johnston, N., & Delibovi, D. Lymphoma therapy and adverse events: nursing strategies for thinking critically and acting decisively. Clinical Journal of Oncology Nursing. 2017;21(1): 2-12.
CLINICAL ACTIVITIES
Certification:
1992-2004 - Oncology Nursing Certification, Oncology Nursing Certification Corp., Pittsburgh, PA.
March, 2001-
Present A.N.C.C. Certified Registered Acute Care Nurse Practitioner
Licensure:
(R.N./C.R.N.P-A.C.) MD #: R104039
ORGANIZATIONAL ACTIVITIES
Professional Organizations:
Oncology Nursing Society
Sigma Theta Tau
Contact this candidate